Malaria Breakthrough: Vaccines and Targeted Treatments Offer Hope for Vulnerable Infants

The past several days have seen significant developments in the global fight against malaria, with particular focus on vaccines and targeted treatments for young children. Malaria remains a widespread and deadly disease, especially in Africa, where children under five years old continue to account for more than 70 percent of malaria deaths, according to the Africa CDC.

One of the standout moments this week came on July 8, when Novartis announced Swissmedic’s approval of Coartem Baby (Riamet Baby), making it the first malaria medication specifically indicated for newborns and young infants. This approval is particularly crucial, as until now, treatments were only available for infants weighing over 4.5 kilograms, leaving a critical gap for the most vulnerable newborns at risk of rapid malaria complications. Previously, these infants had to receive medications designed for older children, increasing their risk of overdose and toxicity. The new therapy, developed in partnership with the Malaria for Medicines Venture and supported by data from the Phase II/III CALINA study, is indicated for babies weighing as little as 2 kilograms and addresses acute, uncomplicated infections due to Plasmodium falciparum. Novartis intends to introduce Coartem Baby in malaria-endemic areas on a primarily not-for-profit basis, and regulatory pathways are now opening in eight African countries that participated in its development. The drug's approval marks a major step forward in protecting infants who previously had limited options for targeted care. Novartis CEO Vas Narasimhan expressed pride in this milestone, emphasizing the company’s decades-long commitment to delivering scientific breakthroughs where they're most needed.

Simultaneously, the international community is pressing ahead with broader immunization efforts. On June 25, Gavi, the Vaccine Alliance, concluded its latest replenishment cycle at the Health and Prosperity through Immunization Global Summit in Brussels. Gavi secured over $9 billion in commitments aimed at saving at least eight million lives and protecting 500 million children between 2026 and 2030 from diseases preventable through vaccines, including malaria. However, a funding gap emerged after the United States announced it would halt all contributions, raising concerns about vaccine safety—a claim Gavi has robustly refuted. According to the Malaria Consortium, this $2.9 billion deficit could lead to the deaths of more than 1.2 million children in low- and middle-income countries over the next five years unless the shortfall is urgently filled. Gavi is exploring innovative financing models to ensure its progress is not reversed, with particular emphasis on sustaining momentum in malaria vaccine rollouts.

On the African continent, individual countries continue their own vaccine implementation strategies. For instance, Nigeria approved the R21/Matrix-M malaria vaccine in April 2023, joining Ghana and leading a push for expanded use across high-burden regions. Progress in vaccine access has the potential to dramatically cut malaria mortality rates among children and further strengthen global disease control.

These advancements in both vaccines and medications underscore the critical importance of sustained political will and donor investments. As health alliances like Gavi and pharmaceutical innovators such as Novartis push forward, the focus remains firmly on reaching every child in need of life-saving protection, ensuring that recent scientific and policy breakthroughs translate into tangible progress on the ground.

This content was created in partnership and with the help of Artificial Intelligence AI

Episode Transcript

Speaker 1 (00:00):
The past several days have seen significant developments in the
global fight against malaria, with particular focus on vaccines and
targeted treatments for young children. Malaria remains a widespread and
deadly disease, especially in Africa, where children under five years
old continue to account for more than seventy percent of
malaria deaths according to the Africa CDC. One of the

(00:24):
standout moments this week came on July eighth, when Novardes
announced Swiss Medics approval of cortem baby ryam at baby,
making it the first malaria medication specifically indicated for newborns
and young infants. This approval is particularly crucial as until now,
treatments were only available for infants weighing over four point

(00:44):
five kilograms, leaving a critical gap for the modable newborns
at risk of rapid malaria complications. Previously, these infants had
to receive medications designed for older children, increasing their risk
of overdose and toxicity. The new therapy, developed in partnership
with the Malaria for Medicine's Venture and supported by data

(01:05):
from the Phase two three Kalina study, is indicated for
babies weighing as little as two kilograms and addresses acute
uncomplicated infections due to Plasmodium falciperum. Novardies intends to introduce
cordum Baby in malaria endemic areas on a primarily not
for profit basis, and regulatory pathways are now opening in

(01:26):
eight African countries that participated in its development. The drug's
approval marks a major step forward in protecting infants who
previously had limited options for targeted care. Novarda CEO vas
Narisiman expressed pride in this milestone, emphasizing the company's decades
long commitment to delivering scientific breakthroughs where they're most needed. Simultaneously,

(01:49):
the international community is pressing ahead with broader immunization efforts.
On June twenty fifth, GAVI, the Vaccine Alliance, concluded its
latest replenishments cycle at the Health and Prosperity through Immunization
Global Summit in Brussels. GAVI secured over nine billion dollars
in commitments aimed at saving at least eight million lives

(02:11):
and protecting five hundred million children between twenty twenty six
and twenty thirty from diseases preventable through vaccines, including malaria. However,
a funding gap emerged after the United States announced it
would halt all contributions, raising concerns about vaccine safety, a
claim GAVI has robustly refuted. According to the Malaria Consortium,

(02:33):
this two point nine billion dollar deficit could lead to
the deaths of more than one point two million children
in low and middle income countries over the next five
years unless the shortfall is urgently filled. GAVI is exploring
innovative financing models to ensure its progress is not reversed,
with particular emphasis on sustaining momentum in malaria vaccine rollouts

(02:57):
on the African Continent. Individual countries conte can you their
own vaccine implementation strategies. For instance, Nigeria approved the R
twenty one Matrix M malaria vaccine in April twenty twenty three,
joining Ghana and leading a push for expanded use across
high burden regions. Progress in vaccine access has the potential

(03:17):
to dramatically cut malaria mortality rates among children and further
strengthen global disease control. These advancements in both vaccines and
medications underscore the critical importance of sustained political will and
donor investments. As health alliances like GAVI and pharmaceutical innovators
such as Novartes push forward. The focus remains firmly on

(03:39):
reaching every child in need of life saving protection, ensuring
that recent scientific and policy breakthroughs translate into tangible progress
on the ground.